These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 25110258)

  • 1. Miscellaneous adverse events with biologic agents (excludes infection and malignancy).
    Feuerstein JD; Cheifetz AS
    Gastroenterol Clin North Am; 2014 Sep; 43(3):543-63. PubMed ID: 25110258
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
    Magro F; Portela F
    BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of biologic agents in pregnancy and breastfeeding.
    Horst S; Kane S
    Gastroenterol Clin North Am; 2014 Sep; 43(3):495-508. PubMed ID: 25110255
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Review article: managing the adverse events caused by anti-TNF therapy in inflammatory bowel disease.
    Shivaji UN; Sharratt CL; Thomas T; Smith SCL; Iacucci M; Moran GW; Ghosh S; Bhala N
    Aliment Pharmacol Ther; 2019 Mar; 49(6):664-680. PubMed ID: 30735257
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The association of psoriasiform rash with anti-tumor necrosis factor (anti-TNF) therapy in inflammatory bowel disease: a single academic center case series.
    Afzali A; Wheat CL; Hu JK; Olerud JE; Lee SD
    J Crohns Colitis; 2014 Jun; 8(6):480-8. PubMed ID: 24268978
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New onset idiosyncratic liver enzyme elevations with biological therapy in inflammatory bowel disease.
    Shelton E; Chaudrey K; Sauk J; Khalili H; Masia R; Nguyen DD; Yajnik V; Ananthakrishnan AN
    Aliment Pharmacol Ther; 2015 May; 41(10):972-9. PubMed ID: 25756190
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety of infliximab and other biologic agents in the inflammatory bowel diseases.
    Reddy JG; Loftus EV
    Gastroenterol Clin North Am; 2006 Dec; 35(4):837-55. PubMed ID: 17129816
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biologic-Induced Infections in Inflammatory Bowel Disease: The TNF-α Antagonists.
    McConachie SM; Wilhelm SM; Bhargava A; Kale-Pradhan PB
    Ann Pharmacother; 2018 Jun; 52(6):571-579. PubMed ID: 29363355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Biologic therapies in inflammatory bowel disease: anti-TNF and new therapeutic targets].
    Flamant M; Bourreille A
    Rev Med Interne; 2007 Dec; 28(12):852-61. PubMed ID: 17628232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-nuclear antibody positivity and the use of certolizumab in inflammatory bowel disease patients who have had arthralgias or lupus-like reactions from infliximab or adalimumab.
    Verma HD; Scherl EJ; Jacob VE; Bosworth BP
    J Dig Dis; 2011 Oct; 12(5):379-83. PubMed ID: 21955431
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dermatological adverse reactions during anti-TNF treatments: focus on inflammatory bowel disease.
    Mocci G; Marzo M; Papa A; Armuzzi A; Guidi L
    J Crohns Colitis; 2013 Nov; 7(10):769-79. PubMed ID: 23453887
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Adverse effects of conventional DMARDs and biologic DMARDs].
    Suzuki Y; Saito E; Wakabayashi T; Suwa A
    Nihon Rinsho; 2007 Oct; 65 Suppl 8():209-17. PubMed ID: 18074541
    [No Abstract]   [Full Text] [Related]  

  • 13. Focus on Anti-Tumour Necrosis Factor (TNF)-α-Related Autoimmune Diseases.
    Lopetuso LR; Cuomo C; Mignini I; Gasbarrini A; Papa A
    Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37175894
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of biologics and the role of therapeutic monitoring.
    Lin K; Mahadevan U
    Gastroenterol Clin North Am; 2014 Sep; 43(3):565-79. PubMed ID: 25110259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study.
    Deepak P; Sifuentes H; Sherid M; Stobaugh D; Sadozai Y; Ehrenpreis ED
    Am J Gastroenterol; 2013 Jan; 108(1):99-105. PubMed ID: 23032984
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of the tumor necrosis factor antagonists in the treatment of inflammatory bowel disease: an update.
    Leso V; Leggio L; Armuzzi A; Gasbarrini G; Gasbarrini A; Addolorato G
    Eur J Gastroenterol Hepatol; 2010 Jul; 22(7):779-86. PubMed ID: 19786877
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autoimmune hepatitis and anti-tumor necrosis factor alpha therapy: A single center report of 8 cases.
    Rodrigues S; Lopes S; Magro F; Cardoso H; Horta e Vale AM; Marques M; Mariz E; Bernardes M; Lopes J; Carneiro F; Macedo G
    World J Gastroenterol; 2015 Jun; 21(24):7584-8. PubMed ID: 26140007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overall and comparative safety of biologic and immunosuppressive therapy in inflammatory bowel diseases.
    Holmer A; Singh S
    Expert Rev Clin Immunol; 2019 Sep; 15(9):969-979. PubMed ID: 31322018
    [No Abstract]   [Full Text] [Related]  

  • 19. Safety of anti-TNF therapy in inflammatory bowel disease during pregnancy.
    Khan N; Asim H; Lichtenstein GR
    Expert Opin Drug Saf; 2014 Dec; 13(12):1699-708. PubMed ID: 25406728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-tumor necrosis factor-α therapy in uveitis.
    Cordero-Coma M; Sobrin L
    Surv Ophthalmol; 2015; 60(6):575-89. PubMed ID: 26164735
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.